COVID-19 Vaccines (2026-2027 Formula) — FDA Approves XFG-Targeted Shots on Aug. 27, 2026
FDA approved the 2026-2027 COVID-19 vaccine formula targeting JN.1-lineage XFG on Aug. 27, 2026, for adults 65+ and ages 5-64 with a high-risk condition.
What FDA approved
On August 27, 2026, the U.S. Food and Drug Administration approved updated COVID-19 vaccines built on the 2026-2027 formula. The approvals came as supplemental Biologics License Applications for products already licensed in the United States, meaning the vaccines are strain-updated versions of existing approved products rather than newly licensed ones. Pfizer and BioNTech received approval for COMIRNATY XFG, and Moderna received approvals for updated 2026-2027 formulations of Spikevax and mNEXSPIKE.[1][3]
Why the formula changed
Like influenza vaccines, COVID-19 vaccines are periodically reformulated to track circulating virus lineages. For the 2026-2027 season, FDA advised manufacturers that the vaccine should be a monovalent product targeting the JN.1-lineage XFG variant, a decision grounded in surveillance of which lineages were dominant heading into fall. The strain-selection guidance preceded the approvals by several months, giving manufacturers time to produce and fill doses ahead of the respiratory virus season.[2][4]
Who the vaccine is approved for
The approved indication is narrower than in the earliest years of COVID-19 vaccination. It covers adults 65 years and older, along with people ages 5 through 64 who have at least one underlying medical condition that places them at higher risk of severe outcomes. Reporting on the approvals described that risk list as including obesity, diabetes, chronic heart or lung disease, immunocompromising conditions and pregnancy, among others. People outside those groups should confirm eligibility with a pharmacist or clinician rather than assuming access.[1][4]
Approval versus coverage
An FDA approval establishes that a vaccine is safe and effective for its labeled population, but it does not by itself determine what insurers must pay for. Under the Affordable Care Act, a recommendation from the CDC's Advisory Committee on Immunization Practices is the trigger for no-cost-sharing coverage of a vaccine by most private plans. At the time of the August 2026 approvals, that ACIP step had not yet been completed, leaving a gap between availability and guaranteed coverage that consumers should verify with their own plan.[4][5]
Verified facts
Cross-checked against 2+ independent sourcesThis section contains facts cross-checked against multiple sources.
The U.S. Food and Drug Administration approved updated COVID-19 vaccines using the 2026-2027 formula on August 27, 2026, covering products from Pfizer-BioNTech and Moderna.[1][3] 2 sources
FDA advised manufacturers that the 2026-2027 formula should be a monovalent vaccine targeting the JN.1-lineage XFG variant of SARS-CoV-2, replacing the prior season's composition.[2][4] 2 sources
The approved indication covers adults 65 years and older, plus individuals ages 5 through 64 who have at least one underlying medical condition raising their risk of severe COVID-19 outcomes.[1][4] 2 sources
Pfizer and BioNTech's updated product is marketed as COMIRNATY XFG, while Moderna received approval for updated 2026-2027 formulations of both Spikevax and mNEXSPIKE.[1][3] 2 sources
Manufacturers stated that shipping of the updated vaccines would begin immediately following approval, with doses reaching pharmacies, hospitals and clinics across the United States within days.[1][5] 2 sources
Reported, not confirmed
Not cross-checked — do not read as factFrom here on: claims and speculation that are not cross-checked.
Underlying conditions qualifying people ages 5-64 for the updated shot include obesity, diabetes, chronic heart or lung disease, immunocompromising conditions and pregnancy, among others on the CDC's risk list.[4] single-source ×1 · Healio summary of FDA labeling and CDC risk-condition list
A CDC Advisory Committee on Immunization Practices recommendation, which triggers insurance coverage requirements under the Affordable Care Act, was still pending at the time of the FDA approvals.[4] single-source ×1 · Healio reporting on ACIP scheduling
Timeline
- 2026-05-22
FDA advisers review strain-selection data and FDA issues guidance that the 2026-2027 formula should be a monovalent JN.1-lineage XFG vaccine.[2]
- 2026-08-27
FDA approves supplemental Biologics License Applications for the Pfizer-BioNTech and Moderna 2026-2027 formula COVID-19 vaccines.[1][3]
- 2026-08-28
Trade and medical press report the approvals; manufacturers say shipping has begun.[4][5]
- Model
- claude-fable-5
- Time
- 08/30/2026, 10:00
- Tokens
- 8,000
- Sources
- 5 sources adopted
- Model
- claude-fable-5 (review pass)
- Time
- 08/30/2026, 10:00
- Tokens
- 3,000
- Verdict
- Passed
| 08/30/2026, 10:00 | First authored (claude-fable-5) | Created |
Frequently asked
Who qualifies for the 2026-2027 COVID-19 vaccine?
The FDA-approved indication covers adults 65 and older, and people ages 5 through 64 who have at least one underlying medical condition that raises their risk of severe COVID-19. Individual pharmacy and insurer policies can differ, so check with your provider before scheduling.
What variant does the 2026-2027 COVID vaccine target?
FDA directed manufacturers to produce a monovalent vaccine targeting the JN.1-lineage XFG variant. That replaces the composition used in the 2025-2026 season.
When will the updated COVID shots be available?
Manufacturers said shipping began immediately after the August 27, 2026 approvals, with doses expected in pharmacies, hospitals and clinics across the U.S. within days.
Will insurance cover the 2026-2027 COVID vaccine?
FDA approval and CDC recommendation are separate steps. A recommendation from the CDC's Advisory Committee on Immunization Practices is what triggers no-cost coverage requirements under the Affordable Care Act, and that step was still pending when the approvals were issued. Coverage may vary until it is finalized.
Official links
Sources
- [1] Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine primary
- [2] COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026 primary
- [3] Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines primary
- [4] FDA approves latest round of COVID-19 shots
- [5] FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season